Company performance
Add to research
Current Price
as of Jun 20, 2025$1.37
P/E Ratio
N/A
Market Cap
$388.1M
Description
Add to research
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerERAS
- Price$1.37-2.14%
Trading Information
- Market cap$388.10M
- Float56.69%
- Average Daily Volume (1m)1,799,910
- Average Daily Volume (3m)1,652,680
- EPS-$0.62
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$30.97M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$34.81M
- EV$134.29M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B0.97
- Debt/Equity12.72
Documents
Add to research
SEC Filings